1Operating Unit of Metabolic Syndrome,
2Operating Unit Internal Medicine, Ospedale di Pavullo,
3Division of Surgery and Surgical Oncology,
4Surgery Academic Clinical Program and Office of Education,
5Division of Gastroenterology,
6Division of Gastroenterology,
7Programme in Cardiovascular and Metabolic Disorders,
© The Author(s) 2020. Open Access This article is licensed under a Creative Commons Attribution 4.0 International License (https://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, sharing, adaptation, distribution and reproduction in any medium or format, for any purpose, even commercially, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.
Nonalcoholic fatty liver disease (NAFLD) exhibits sexual dimorphism, with men being more exposed than women to the risk of simple steatosis, nonalcoholic steatohepatitis fibrosis, and hepatocellular carcinoma (HCC), while the protection conferred to women seemingly disappears with aging and reproductive senescence (i.e., menopause). HCC, the most common primary liver cancer, which carries an ominous prognosis, may result from various genetic and non-genetic risk factors. NAFLD is now projected to become the most common cause of HCC. HCC also exhibits a definite sexual dimorphism in as much as it has a worldwide high male-to-female ratio. In this review article, we focus on sex differences in the epidemiological features of HCC. Moreover, we discuss sex differences in the clinical outcome and molecular pathobiology of NAFLD-HCC. By highlighting the research gaps to be filled, the aim of this review is to prompt future research of sex differences in HCC and facilitate developing personalized cancer prevention strategies, detection, and treatments to achieve better patient outcomes in NAFLD-HCC, considering sex differences in HCC pathobiology.
Liver cancer, pathobiology, personalized medicine, sex differences
Hepatocellular carcinoma (HCC), the most common primary liver cancer (PLC), carries an ominous prognosis, and is the fourth most common cause of mortality owing to cancer[1,2]. The chief modifiers of HCC risk include geographic variability, demographics and severity of liver disease. Cirrhosis, irrespective of aetiology, increases the risk of HCC. On a global basis, the proportion of HCCs attributed to nonalcoholic fatty liver disease (NAFLD) is increasing owing to trajectories of declining HCV infection and escalating NAFLD[1,3,4]. Additional risk factors for the development of HCC are infection with HBV, alcoholic liver disease, aflatoxin, and genetic haemochromatosis.
Spanning a wide range of liver histology changes, NAFLD faithfully recapitulates the whole spectrum of alcoholic liver disease though it is observed in the nonalcoholic patient and in the absence of other competing causes of (steatogenic) liver disease. Similar to HCC, NAFLD accounts for a substantial clinical burden and exacts a heavy toll of healthcare-related expenses.
Sex disparities in various human diseases, from initial manifestations to disease outcome, are often encountered in clinical practice. In fact, sex and gender act as powerful modifiers of the top ten causes of mortality and morbidity, including heart disease, cancer, chronic lung disease, Alzheimer’s disease, influenza and pneumonia, chronic kidney and chronic liver diseases. Clear sex disparity exists in HCC, which is twice as common in men as in women. NAFLD also exhibits multifaceted sexual dimorphism[10,11]. It occurs more often in men than in women of fertile age and is heavily affected by reproductive status. Understanding these sex differences is the key to deciphering the pathophysiology of the disease as well as in guiding personalized care.
On this background of evidence, we aimed at illustrating our current knowledge of sex differences in HCC and clarifying gaps to be filled in future research, while placing special focus on NAFLD-related HCC.
The PubMed database was extensively searched for articles published as of the 31st of July 2020. The keywords used in our search include, but are not limited to: HCC, liver cancer, sex differences, gender differences, epidemiology, natural course, pathogenesis, risk factors, immune response, genetics, and sex hormones. Additional terms were used to search for articles reporting sex differences and/or the effect of sex hormones in specific mechanisms pertaining to carcinogenesis. Among the retrieved publications, only those that were deemed to be relevant based on consensus among the authors were retained.
Irrespective of its aetiology, HCC affects men more commonly than women owing to complex and multi-factorial reasons. This section reviews risk factors of HCC in general and discusses interactions between sex and risk factors.
Eastern Asia, Southeast Asia, and sub-Saharan Africa exhibit a high incidence and prevalence of HCC; Mongolia, China, Japan, Papua New Guinea, and Egypt are top-ranked countries. By contrast, countries with a low incidence and prevalence include India, Russia, northern countries of South America, Argentina, European countries (except for southern countries), USA, and Australia with the rest of the world exhibiting intermediate rates of incidence and prevalence.
Multi-ethnic populations display a clear ethnic gradient. For example, in the United States, Asians/Pacific Islanders have been reported to have the highest incidence rate per 100,000 (11.7), followed by Hispanics (9.5), Blacks (7.5), while Whites had the lowest (4.2).
With few exceptions, the male to female (M:F) ratio of the incidence of HCC ranges between 2 to 3 in the most of the countries, irrespective of whether they are high-rate areas or not, and are maximal in middle European countries (M:F ratio up to 5)[13,14]. In contrast, in Costa Rica, Colombia, Ecuador and Uganda, the M:F ratio of the incidence of HCC is smaller, ranging from 1.3 to 1.6[13,14].
The biological grounds underlying this sex disparity in the prevalence of HCC are incompletely defined and probably related to multiple behavioural, hormone-metabolic risk factors, and cancer biology. Sex differences in HCC pathogenesis are discussed below under sex disparity in HCC pathobiology.
The difference in the M:F ratio of the incidence of HCC among different countries is intriguing, suggesting potential race/ethnicity-sex interplay in HCC. At this point, sufficient data do not exist to delineate whether the difference is explained by a biological interplay and/or an interplay of gender attributes and culture/ethnicity.
The overall incidence of HCC consistently peaks at 70 years in various countries worldwide, such as France, Italy, Japan, and USA (whites) and this is approximately 5-15 years before the peak occurrence of cholangiocarcinoma, the second most common PLC after HCC. However, other authors report that the mean ages of diagnosis with HCC are 55-59 years in China and 63-65 years in Europe and North America. In Qidong, China, where the HCC burden is among the world’s highest, the age-specific incidence rates increase up to the age of 45 among men and then plateau; while increasing to the age of 60 and then plateauing among women. A surveillance, epidemiology, and end results (SEER) Analysis (from 1988 to 2010) including 39,345 patients with HCC (Men 76%, women 34%) showed that men are diagnosed 4-7 years earlier than women across the race/ethnic groups. These findings suggest that sex and age interact in the occurrence of HCC, implying that consideration of this interaction (as opposed to treating age and sex as independent variables) will be essential in future research.
While cirrhosis is an almost essential pre-requisite for the development of HCC in those with HCV infection, infection with HBV exerts a more direct carcinogenic effect on the liver. Similar to HBV infection and to alcoholic liver disease, NAFLD-HCC may occur in non-cirrhotic livers[14,15]. A Japanese descriptive study reported that men with nonalcoholic steatohepatitis (NASH) developed HCC at earlier liver fibrosis stages than women. The study was too small to confirm the sex difference but provides an intriguing hypothesis pertaining to carcinogenesis. Further larger studies are warranted to investigate this.
With the exceptions of Japan and Egypt (where HCV infection is the chief risk factor of HCC), in most high-risk countries, chronic HBV infection and aflatoxin B1 are the major risk factors for the development of HCC, whereas HCV infection, excessive alcohol consumption, and common metabolic disorders (diabetes, obesity and metabolic syndrome) prevail in low-rate areas. Chronic drinking of alcohol > 80 g/day for over 10 years increases the risk of HCC by a factor of 5; and alcohol consumption enhances the risk of HCC in those with either chronic hepatitis C or NAFLD[10,18]. However, given that these data often combine both sexes, research needs to be conducted urgently to clarify the sex-specific thresholds of alcohol consumption that are associated with a raised HCC risk.
HCC commonly exhibits familial clustering, and family history of disease is a risk factor for the development of HCC. Interestingly, family history of HCC was identified as a favourable prognostic factor for improved survival particularly in those individuals whose tumours can be radically cured, even in the stage-stratified analysis. In the study, female sex and younger age, non-diabetics, and lifetime non-drinkers were more common among individuals with first-degree family histories of HCC than among those without such histories. The exact mechanisms underlying the above associations remain uncertain.
Genetic variants associated with an increased risk of NAFLD, advanced NAFLD, and NAFLD-HCC appear to contribute to the risk of HCC in the general population. A recent study conducted using Danish and UK databases demonstrated that a genetic risk score using three genetic variants [i.e., patatin-like phospholipase domain-containing protein 3 (PNPLA3) p.I148M, transmembrane 6, superfamily member 2 (TM6SF2) p.E167K, and hydroxysteroid 17-beta dehydrogenase 13 (HSD17B13) rs72613567], is associated with an up to 12-fold higher risk of cirrhosis and up to a 29-fold higher risk of HCC in individuals from the general population from these countries.
Certain inheritable metabolic disorders such as hemochromatosis, α-1 antitrypsin deficiency, tyrosinemia, glycogen storage diseases and several porphyrias also increase HCC risk, although they account for a negligible HCC risk globally[21,22].
Smoking and co-infection with HIV also contribute to the development of HCC. Certain environmental factors or occupational factors, such as vinyl chloride, polycyclic aromatic hydrocarbons, aflatoxins, and aristolochic acid, a common ingredient of traditional herbal medicine, have been suggested to play a role in the development of HCC[23,24]. How these factors and underlying mechanisms intersect with sex and sex hormones in the development of HCC has not been fully elucidated.
Sexual dimorphisms in metabolism are well-known (recently reviewed elsewhere[9,10,12]) and likely account for sex differences in HCC risk. A few other risk factors have been suggested for sex/gender-interaction, which are also discussed in this section.
Obesity has been associated with a higher risk of HCC incidence in men than women, especially in non-Asians. A recent study conducted in an Asian population found a different relationship between BMI and HCC risk according to sex, following a U-shaped and a linear curve in men and women, respectively. Studies reported a stronger risk association between pre-diabetes/diabetes and HCC in men than women[26-28].
NAFLD has a definite sexual dimorphism; men are more prone than women to the risk of uncomplicated steatosis, NASH fibrosis, and HCC. However, aging and menopause are associated with the disappearance of protection in women[12,29,30].
Prospective studies indicate that regular alcohol intake, although within safe thresholds, is a risk factor for the progression to HCC among individuals with NAFLD. Moreover, among those with HCC, alcohol use is more frequent in men than in women[26,32].
Additionally, men are more prone to acquire HBV and HCV infection, develop chronic hepatitis, cirrhosis and HCC than women.
Recent large epidemiological studies conducted in the USA have shown that, compared to men, women with HCC presented with older age, higher frequency of NAFLD, non-cirrhotic HCC, less-advanced tumour stage (by size, local/vascular invasion, metastasis) and lower frequency of alcoholic liver disease[32-34].
Studies regarding sex differences in survival rates have yielded conflicting results so far. Two recent large multi-centre US studies enrolling 5,327 patients with HCC (22.6% women) and 1,110 (23.5% women), respectively, reported higher overall survival rates among women after adjusting for confounding factors[33,34]. Consistently, one of these found that female sex was independently associated with early tumour detection [odds ratio (OR) 1.46] and response to first HCC treatment (OR 1.72). Conversely, other US studies found no sex-related difference in HCC prognosis[32,35], while Asian studies did[36-39]. Another US study showed age, sex, and ethnicity intersection in survival rates; women had higher survival rates from HCC than men before age 55, while after 65 years or among Hispanics, there was no such a survival difference between sexes. Another US study also suggested a similar interplay of age and sex in HCC survival and further possible age-, sex-, and race/ethnicity-interaction in HCC survival. Table 1 provides a synthetic overview of sex differences in risk factors, presentation, and outcome of HCC owing to NAFLD and non-NAFLD aetiologies. Future studies with proper consideration of these interactions are warranted to reconcile some inconsistency in the literature.
Sex differences in risk factors, presentation, and outcome of HCC owing to NAFLD and non-NAFLD aetiologies
|Authors||Study characteristics||Sex differences|
|Risk factors||Tumour features||Outcome|
|Yang et al.||Retrospective cohort from a national registry, US, 39345 HCC patients, 9557 (24%) F, diagnosed between 1988-2010||F older age (67 years vs. 61 years)||F more liver-limited (32% vs. 26%) and less metastatic (14% vs. 16%) disease||F better overall survival (11 months vs. 10 months; HR 0.93) independent of age, race, disease stage, or treatment. The protective effect of sex was greatest in patients aged 18-44 years (14 months vs. 10 months; HR 0.75) and it was lost after 65 years. No survival sex difference among Hispanics|
|Ladenheim et al.||Retrospective cohort, US, 1,886 HCC patients, 437 (23.2%) F, diagnosed between 1998-2015||F older age (64 years vs. 60 years); M more HCV+ (43% vs. 37%), alcohol use (63% vs. 35%) and smoking (58% vs. 31%)||F less likely to present with tumours > 5 cm (30% vs. 40%) and more likely to be diagnosed by routine screening (66% vs. 58%)||No significant difference in median survival (30.7 months vs. 33.1 months)|
|Wu et al.||Retrospective cohort single centre, Hawaii (US), 1,206 HCC patients, 307 (25%) F, diagnosed between 1993-2017||F older age (66.0 years vs. 62 years), more NAFLD/ NASH (22% vs. 7%)
M more HCV+ (43% vs. 37%), alcohol (53% vs. 12%) and smoking (68% vs. 38%)
|F smaller mean size at diagnosis (5 cm vs. 6 cm), less vascular invasion (7.5% vs. 12%). F more likely to undergo HCC surveillance but less to undergo liver transplant||Similar overall survival.
Mortality predictors at MVA: NAFLD/NASH for both M and F, age and smoking for M. Transplant predictive of survival for M
|Lai et al.||Retrospective cohort single centre, Asia (Taiwan), 516 consecutive HCC patients, 118 (22.9%) F, who received surgical resection between 2000-2007, F-up > 10 years||F more HCV + (37% vs. 23%); lower HBV + (59% vs. 73%)||F less micro-vascular invasion (25% vs. 36%)||Similar overall survival. F better recurrence-free survival and distant metastasis-free survival in patients with alpha-fetoprotein ≤ 35 ng/mL, independent of other clinical variables|
|Rich et al.||Retrospective cohort single centre, US, 1,110 HCC patients, 258 (23.5%) F, diagnosed between 2008-2017||F older age (63 years vs. 59 years), more NAFLD (27% vs. 8%)
M more alcohol alone (17% vs. 5%) or with HCV+ (33% vs. 15%)
|F vs. M earlier- BCLC stage tumours (53% vs. 44%)
but similar liver function
|F < 65 years had better overall survival than M (18.3 months vs. 11.2 months). However, older F and M had similar overall survival (15.5 months vs. 15.7 months) at UVA
F sex associated with lower mortality (HR 0.82), early tumour detection (OR 1.46) and response to first HCC treatment (OR 1.72) at MVA
|Phipps et al.||Retrospective cohort multi-centric, US, 5,327 HCC patients, 1,203 (22.6%) F, diagnosed between 2000-2014||F more NAFLD (23% vs. 12%) and less alcoholic liver disease (5% vs. 15%)||Non-cirrhotic HCC higher among F (17% vs. 10%). F less-advanced HCC by tumour, node, metastasis staging and a higher proportion within Milan criteria (39% vs. 35%)||F greater overall survival (2.5 ± 2.9 years vs. 2.2 ± 2.7 years)|
Chronic persistent injury induces wound-healing responses through the release of pro-inflammatory cytokines (e.g., IL-6, TNF-alpha) and increased oxidative stress in the liver. The wound-healing process, together with persistent liver damage, promotes fibrogenesis and tissue DNA damages and facilitates hepatic carcinogenesis. The liver tissue concentration of 8-OHdG, a marker of oxidative DNA damage, has been associated with epigenetic inactivation of tumour suppressor genes (i.e., methylated tumour suppressor genes)[42,43]. An increased number of methylated tumour suppressor genes was, in its turn, associated with a shorter time-to-HCC development in patients with chronic hepatitis C, demonstrating a mechanistic link of oxidative DNA damage, epigenetic alteration of tumour suppressor genes, and development of HCC. In NAFLD patients, chronic metabolic stress to hepatocytes aggravates oxidative stress, induces cellular protein/DNA damage, and promotes premature senescence of hepatocytes, contributing to an increased risk of HCC among obese individuals[12,45], even in the absence of cirrhosis.
Sex differences are well documented in cancer mechanisms. Several well studied mechanisms accounting for sex differences are summarized in Table 2[47-56]. Compared to females, males are more susceptible to oxidative stress due to a higher NADPH oxidase activity, a lower NFR-2, and lower anti-oxidants[51,52,57], and have a higher induction of IL-6 by hepatic Kupffer cells under liver injury. In contrast, higher physiological oestrogens protect females from HCC development via the anti-oxidative effects of estrogenic[51,57], anti-fibrotic effects, and inhibitory effects on IL-6 production by hepatic Kupffer cells. The protective effects of oestrogen are lost after menopause, which may explain the fact that the male predominance observed in HCC incidence decreases with advancing age. Gut microbiota also exhibits sex differences[56,59-61]. In an experimental mouse model, higher hepatic hydrophobic bile acids were observed in males, which was causally associated with a decreased expression of tumour-suppressive microRNA in the liver and increased incidence of HCC. Importantly, similar sex differences in bile acid profile exist in humans, suggesting that sex-differences in gut microbiota and bile acid profile may contribute to male dominance in the development of HCC in man.
Sex differences relevant to the pathomechanisms of HCC in NAFLD
|Authors||Study characteristics||Sex differences|
|Risk factors||Outcome||Impact on HCC|
|Pre-hepatic factors increasing hepatic metabolic stress|
|Lemieux et al.||Total body fat and abdominal adipose tissue were evaluated in 89 men and 75 women using CT||Visceral adiposity||After adjusting for total body fat mass, men had significantly higher values of visceral adipose tissue volume and areas, measured by CT, than women. An increase in total fat mass was associated with a significantly greater increase in visceral adipose tissue volume in men than in women||Higher FFA release in males induces inflammation, insulin resistance, and lipotoxicity and fosters a tumour-promoting environment in the liver and may contribute to an increased recurrence of HCC|
|Laughlin et al.||A cross-sectional study to measure serum leptin, adiponectin and sex hormone levels in 1510 community dwelling men and postmenopausal women aged 50-92 years||Visceral adipokines||Serum adiponectin and leptin levels were higher in women than in men. In both sexes, adiponectin concentrations were lower, and leptin levels higher, with increasing BMI and waist girth||A higher adiponectine level may protect women from developing HCC via the activation of AMPK and p38α|
|Lönnqvist et al.||BMI and age matched obese subjects (22 male and 23 female) undergoing elective surgery were evaluated for visceral fat lypolysis||Visceral fat lipolysis||Catecholamine-induced rate of FFA mobilization from visceral fat to the portal venous system is higher in obese men than in obese women, probably due to a larger fat-cell volume but also to a decrease in the function of α2-adrenoceptors, an increase in the function of β3-adrenoceptors, and an increased ability of cyclic AMP to activate hormone-sensitive lipase||Higher FFA release in males induces inflammation, insulin resistance, and lipotoxicity and fosters a tumour-promoting environment in the liver and may contribute to an increase recurrence of HCC|
|Augustine et al.||Compared Nqo1 mRNA and protein expression and activity in males and females before and after applying known inducers using SD and August Copenhagen x Irish (ACI) rat strains||NAD(P)H: quinone oxidoreducatase 1 (Nqo1)||ACI rats showed minimal differences in Nqo1. In SD rats, Nqo1 mRNA, protein, and activity levels were significantly higher in females than in males. Female SD rats showed greater induction than male||Higher Nqo1 may lead to greater protection against oxidative stress and thus decreased susceptibility to carcinogens|
|Kratschmar et al.||The interaction among corticosteroid, 11b-HSD1, and NFR-2 was evaluated using transfected HEK-293 cells and hepatic H4IIE cells. The hepatic expression levels of 11b-HSD1 and NFR-2 target genes were also compared between male and female Han Wistar rats||NFR-2||The study using the cell lines demonstrated that glucocorticoids, activated by 11b-HSD1 and acting through GR, suppress the Nrf2-dependent antioxidant response. This research also demonstrated that the hepatic expression of 11b-HSD1 was higher in male rats vs. female rats while the Nrf-2 target genes (HMOX1, NQO1 and ABCC3) were lower in male vs. female rats, confirming the above-demonstrated pathway||Higher activity of 11b-HSD1 and/or corticosteroid may lead to suppressed antioxidant response, which may lead to higher oxidative DNA damage|
|Hofer et al.||DNA SSB and ALS were measured in blood samples from 99 subjects (age: 19-31 years) living in Stockholm, Sweden. Oxidative DNA damage was also analyzed using the DNA repair glycosylase FPG as well as HPLC-ECD for specific analysis of 8-oxodG||Oxidative DNA damage||Males had higher levels of SSB + ALS than females, although no difference was seen for oxidative lesions. There was no correlation between FPG sites and 8-oxodG. In females, there was a positive correlation between FPG levels and BMI and a negative correlation between SSB + ALS and fruit intake||Men are associated with a higher risk of oxidative DNA damage|
|Naugler et al.||In mice administered with DEN, HCC incidence, and its relationship with hepatic IL-6 induction, Toll-like receptor adaptor protein MyD88, and oestrogen were evaluated in male and female mice||IL-6||A higher HCC incidence was observed in male vs. female DEN-induced hepatocarcinogenesis model. The higher incidence of HCC in males was associated with higher MyD88-dependent induction of IL-6 in male hepatic Kupffer cells under liver injury. Estradiol inhibited IL-6 production by hepatic Kupffer cells||Higher induction of IL-6 in Kupffer cells under liver injury partly explains higher incidence of HCC in males while estrogens protect females from HCC, in part, via reducing IL-6|
|Yasuda et al.||Using the DEN model, hepatic fibrosis was compared between male and female rats||Stellate cell activation/ fibrogenesis||In male rats the induction of fibrotic response was significantly stronger than in female rats. Estradiol reduced hepatic fibrogenesis in male rats while concomitant administration of a neutralizing antibody against rat estradiol enhanced fibrogenesis. Oophorectomy in the female rats had a fibrogenic effect||Higher oestrogen protects premenopausal women from advanced hepatic fibrosis, a major risk factor of HCC|
|Tumor suppressor genes|
|Xie et al.||The mechanistic link between microbiota and hepatocellular carcinogenesis using a STZ-HFD induced NASH-HCC murine model and compared results for both sexes||Bile acid/microbiota||STZ-HFD feeding induced a higher incidence of HCC in male mice, which was associated with increased intrahepatic retention of hydrophobic BAs and decreased hepatic expression of tumor-suppressive microRNAs.
Metagenomic analysis showed differences in gut microbiota involved in BA metabolism between male and female mice. Treating STZ-HFD male mice with 2% cholestyramine led to significant improvement of hepatic BA retention, tumor-suppressive microRNA expressions, microbial gut communities, and prevention of HCC
|Sex differences in microbiota lead to higher intrahepatic retention of hydrophobic BAs, decreased tumor suppressor microRNA in the liver, and an increased incidence of HCC in male mice|
Despite the fact that evidence supports oestrogen exerting protective effects on the development of HCC, whether oestrogens have protective effects on the progression of HCC and patients’ survival remains uncertain. A few epidemiological studies implicated a potentially favourable effect of oestrogen on HCC survival, by demonstrating a beneficial association of exogenous oestrogen use with overall survival among women with HCC and the better overall survival rates of women compared to men, which, however, disappears in advanced age. However, possible beneficial effects of oestrogen on HCC survival have not been tested in experiments, and the mechanisms, if any, through which oestrogens affect HCC survival, remain uncertain.
HCC tumour tissue expresses oestrogen receptors, although the clinical and pathological significance of these remain controversial[63,64]. The positive expression rates of oestrogen receptors among HCC cases also significantly varies in the literature, probably due to the differences in the methodologies and populations of the studies (e.g., ethnicity, sex), as well as stage and aetiologies of disease. HCC tumour tissues express both oestrogen receptor alpha (ERα) and beta (ERβ), and also a variant form of ERα (vERα), which lacks exon 5 in the hormone-binding domain. Compared to patients with ER-negative HCC, patients with ER-positive HCC have a shorter survival rate after curative resection. Several randomized controlled trials were conducted to ascertain whether blockage of oestrogen signalling in HCC by the anti-oestrogen tamoxifen would improve the survival of patients with HCC. However, the results were consistently negative[67,68]. The presence of the liver vER receptor in the tumour is a strong negative predictor of survival in inoperable HCC patients and is a marker of clinical aggressiveness compared to wild-type ERαn[69,70]. HCC positive for the vER receptor is unresponsive to tamoxifen but responds to megestrol.
Sex differences in HCC biology have extensively been explored in recent years in functional signatures of differentially expressed genes[71,72], expression quantitative trait loci (eQTL), and cancer-driver genes. These studies strongly suggest that HCC in males and females are biologically distinct and may respond differently to treatments. This is in agreement with epidemiological data summarized in Table 1. However, no randomized controlled trials have demonstrated sex differences in HCC treatment response or clinical outcomes. The consideration of sex and women’s reproductive history in clinical studies designs and analyses is warranted in future trials to better understand whether and how these factors may modify treatment response to specific therapeutic targets and influence clinical outcomes.
A robust line of research has shown multifaceted sexual dimorphisms in the NAFLD domain[10-12]. It is important to note that the observed sex differences in NAFLD are not linear throughout the course of the disease but rather mechanism-specific. Further studies will eventually contribute to more effectively reducing the NAFLD-HCC incidence by delineating sex differences in individual pathways and therefore allowing the development of a personalized approach in preventing NAFLD progression. Similarly, sex differences in HCC epidemiology have not been fully characterized with proper consideration of women’s reproductive status/history. Therefore, we recommend that sex/gender and reproductive history should be considered in future clinical and epidemiological HCC studies. Further mechanistic understanding, together with the epidemiological characterization of sex differences and the impact of reproductive history will predictably help clinicians by allowing more accurate risk stratification and personalized therapeutic approaches in the future. A scoring system combining genetic and non-genetic HCC risk factors while considering biological disparities by sex and reproductive status may improve our future care, although sufficient data to develop such a scoring system is pending future research.
We are indebted to Ms. Jacqueline Mole for her careful editing of English.Authors’ contributions
Made substantial contributions to conception and design of the study and performed data analysis and interpretation: Lonardo A, Suzuki A
Wrote the section on the epidemiology: Ballestri S, Lonardo A
Contributed to the section on pathobiology: Chow PKH, Suzuki A
Edited the final draft: Lonardo A, Ballestri S, Chow PKH, Suzuki A
Prepared the revised version of the manuscript based on Reviewers’ suggestions and comments: Lonardo A, Suzuki AAvailability of data and materials
Not applicable.Financial support and sponsorship
None.Conflicts of interest
All authors declared that there are no conflicts of interest.Ethical approval and consent to participate
Not applicable.Consent for publication
© The Author(s) 2020.
1. Yang JD, Hainaut P, Gores GJ, Amadou A, Plymoth A, Roberts LR. A global view of hepatocellular carcinoma: trends, risk, prevention and management. Nat Rev Gastroenterol Hepatol 2019;16:589-604.DOIPubMedPMC
2. Lok AS, Seeff LB, Morgan TR, et al. Incidence of hepatocellular carcinoma and associated risk factors in hepatitis C-related advanced liver disease. Gastroenterology 2009;136:138-48.DOIPubMedPMC
3. Pennisi G, Celsa C, Giammanco A, Spatola F, Petta S. The burden of hepatocellular carcinoma in non-alcoholic fatty liver disease: screening issue and future perspectives. Int J Mol Sci 2019;20:5613.DOIPubMedPMC
4. Estes C, Anstee QM, Arias-Loste MT, et al. Modeling NAFLD disease burden in China, France, Germany, Italy, Japan, Spain, United Kingdom, and United States for the period 2016-2030. J Hepatol 2018;69:896-904.DOIPubMed
5. Fattovich G, Stroffolini T, Zagni I, Donato F. Hepatocellular carcinoma in cirrhosis: incidence and risk factors. Gastroenterology 2004;127:S35-50.DOIPubMed
6. Diehl AM, Goodman Z, Ishak KG. Alcohollike liver disease in nonalcoholics. A clinical and histologic comparison with alcohol-induced liver injury. Gastroenterology 1988;95:1056-62.PubMed
7. Italian Association for the Study of the Liver (AISF). AISF position paper on nonalcoholic fatty liver disease (NAFLD): updates and future directions. Dig Liver Dis 2017;49:471-83.DOIPubMed
8. Younossi ZM, Henry L, Bush H, Mishra A. Clinical and economic burden of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis. Clin Liver Dis 2018;22:1-10.DOIPubMed
9. Mauvais-Jarvis F, Bairey Merz N, Barnes PJ, et al. Sex and gender: modifiers of health, disease, and medicine. Lancet 2020;396:565-82.DOIPubMedPMC
10. Lonardo A, Nascimbeni F, Ballestri S, et al. Sex differences in nonalcoholic fatty liver disease: state of the art and identification of research gaps. Hepatology 2019;70:1457-69.DOIPubMedPMC
11. Balakrishnan M, Patel P, Dunn-Valadez S, et al. Women have a lower risk of nonalcoholic fatty liver disease but a higher risk of progression vs men: a systematic review and meta-analysis. Clin Gastroenterol Hepatol 2020; doi: 10.1016/j.cgh.2020.04.067.DOIPubMed
12. Lonardo A, Suzuki A. Sexual dimorphism of NAFLD in adults. Focus on clinical aspects and implications for practice and translational research. J Clin Med 2020;9:1278.DOIPubMedPMC
13. McGlynn KA, Petricka JL, London WT. Global epidemiology of hepatocellular carcinoma: an emphasis on demographic and regional variability. Clin Liver Dis 2015;19:223-38.DOIPubMedPMC
14. El-Serag HB. Epidemiology of viral hepatitis and hepatocellular carcinoma. Gastroenterology 2012;142:1264-73.e1.DOIPubMedPMC
15. Petrick JL, Braunlin M, Laversanne M, Valery P, Bray F, McGlynn KA. International trends in liver cancer incidence, overall and by histologic subtype, 1978-2007. Int J Cancer 2016;139:1534-45.DOIPubMedPMC
16. Yang D, Hanna DL, Usher J, et al. Impact of sex on the survival of patients with hepatocellular carcinoma: a surveillance, epidemiology, and end results analysis. Cancer 2014;120:3707-16.DOIPubMed
17. Yasui K, Hashimoto E, Komorizono Y, et al. Characteristics of patients with nonalcoholic steatohepatitis who develop hepatocellular carcinoma. Clin Gastroenterol Hepatol 2011;9:428-33. quiz e450PubMed
18. Morgan TR, Mandayam S, Jamal MM. Alcohol and hepatocellular carcinoma. Gastroenterology 2004;127:S87-96.DOIPubMed
19. An J, Chang S, Kim HI, Song GW, Shim JH. The clinical behavior and survival of patients with hepatocellular carcinoma and a family history of the disease. Cancer Med 2019;8:6624-33.DOIPubMedPMC
20. Gellert-Kristensen H, Richardson TG, Davey Smith G, Nordestgaard BG, Tybjaerg-Hansen A, Stender S. Combined effect of PNPLA3, TM6SF2, and HSD17B13 variants on risk of cirrhosis and hepatocellular carcinoma in the general population. Hepatology 2020; doi: 10.1002/hep.31238.DOIPubMed
21. Dragani TA. Risk of HCC: genetic heterogeneity and complex genetics. J Hepatol 2010;52:252-7.DOIPubMed
22. Jang HJ, Yang HR, Ko JS, Moon JS, Chang JY, Seo JK. Development of hepatocellular carcinoma in patients with glycogen storage disease: a single center retrospective study. J Korean Med Sci 2020;35:e5.DOIPubMedPMC
23. Santella RM, Wu HC. Environmental exposures and hepatocellular carcinoma. J Clin Transl Hepatol 2013;1:138-43.DOIPubMedPMC
24. Ng AWT, Poon SL, Huang MN, et al. Aristolochic acids and their derivatives are widely implicated in liver cancers in Taiwan and throughout Asia. Sci Transl Med 2017;9:eaan6446.DOIPubMed
25. Yao KF, Ma M, Ding GY, et al. Meta-analysis reveals gender difference in the association of liver cancer incidence and excess BMI. Oncotarget 2017;8:72959-71.DOIPubMedPMC
26. Chen CL, Kuo MJ, Yen AM, et al. Gender difference in the association between metabolic factors and hepatocellular carcinoma. JNCI Cancer Spectr 2020;4:pkaa036.DOIPubMedPMC
27. Borena W, Strohmaier S, Lukanova A, et al. Metabolic risk factors and primary liver cancer in a prospective study of 578,700 adults. Int J Cancer 2012;131:193-200.DOIPubMed
28. El-Serag HB, Hampel H, Javadi F. The association between diabetes and hepatocellular carcinoma: a systematic review of epidemiologic evidence. Clin Gastroenterol Hepatol 2006;4:369-80.DOIPubMed
29. Lonardo A, Bellentani S, et al; Non-alcoholic Fatty Liver Disease Study Group. Epidemiological modifiers of non-alcoholic fatty liver disease: Focus on high-risk groups. Dig Liver Dis 2015;47:997-1006.DOIPubMed
30. Ballestri S, Nascimbeni F, Baldelli E, Marrazzo A, Romagnoli D, Lonardo A. NAFLD as a sexual dimorphic disease: role of gender and reproductive status in the development and progression of nonalcoholic fatty liver disease and inherent cardiovascular risk. Adv Ther 2017;34:1291-326.DOIPubMedPMC
31. Petroni ML, Brodosi L, Marchignoli F, Musio A, Marchesini G. Moderate alcohol intake in non-alcoholic fatty liver disease: to drink or not to drink? Nutrients 2019;11:E3048.DOIPubMedPMC
32. Wu EM, Wong LL, Hernandez BY, et al. Gender differences in hepatocellular cancer: disparities in nonalcoholic fatty liver disease/steatohepatitis and liver transplantation. Hepatoma Res 2018;4:66.DOIPubMedPMC
33. Rich NE, Murphy CC, Yopp AC, Tiro J, Marrero JA, Singal AG. Sex disparities in presentation and prognosis of 1110 patients with hepatocellular carcinoma. Aliment Pharmacol Ther 2020;52:701-9.DOIPubMedPMC
34. Phipps M, Livanos A, Guo A, et al. Gender matters: characteristics of hepatocellular carcinoma in women from a large, multicenter study in the United States. Am J Gastroenterol 2020;115:1486-95.DOIPubMed
35. Ladenheim MR, Kim NG, Nguyen P, et al. Sex differences in disease presentation, treatment and clinical outcomes of patients with hepatocellular carcinoma: a single-centre cohort study. BMG Open Gastroenterol 2016;3:e000107.DOIPubMedPMC
36. Lam CM, Yong JL, Chan AO, et al. Better survival in female patients with hepatocellular carcinoma: oral contraceptive pills related? J Clin Gastroenterol 2005;39:533-9.DOIPubMed
37. Dohmen K, Shigematsu H, Irie K, et al. Longer survival in female than male with hepatocellular carcinoma. J Gastroenterol Hepatol 2003;18:267-72.DOIPubMed
38. Tangkijvanich P, Mahachai V, Suwangool P, et al. Gender difference in clinicopathologic features and survival of patients with hepatocellular carcinoma. World J Gastroenterol 2004;10:1547-50.DOIPubMedPMC
39. Lai MW, Chu YD, Lin CL, et al. Is there a sex difference in postoperative prognosis of hepatocellular carcinoma? BMC Cancer 2019;19:250.DOIPubMedPMC
40. Li S, Hong M, Tan HY, Wang N, Feng Y. Insights into the Role and Interdependence of Oxidative Stress and Inflammation in Liver Diseases. Oxid Med Cell Longev 2016;2016:423406.DOIPubMedPMC
41. Yang SF, Chang CW, Wei RJ, Shiue YL, Wang SN, Yeh YT. Involvement of DNA damage response pathways in hepatocellular carcinoma. Biomed Res Int 2014;2014:153867.DOIPubMedPMC
42. Nishida N, Kudo M. Oxidative stress and epigenetic instability in human hepatocarcinogenesis. Dig Dis 2013;31:447-53.DOIPubMed
43. O’Hagan HM, Wang W, Sen S, et al. Oxidative damage targets complexes containing DNA methyltransferases, SIRT1, and polycomb members to promoter CpG Islands. Cancer Cell 2011;20:606-19.DOIPubMedPMC
44. Nishida N, Kudo M, Nagasaka T, Ikai I, Goel A. Characteristic patterns of altered DNA methylation predict emergence of human hepatocellular carcinoma. Hepatology 2012;56:994-1003.DOIPubMed
45. Makarova-Rusher OV, Altekruse SF, McNeel TS, et al. Population attributable fractions of risk factors for hepatocellular carcinoma in the United States. Cancer 2016;122:1757-65.DOIPubMedPMC
46. Rubin JB, Lagas JS, Broestl L, et al. Sex differences in cancer mechanisms. Biol Sex Differ 2020;11:17.DOIPubMedPMC
47. Lemieux S, Prud’homme D, Bouchard C, Tremblay A, Després JP. Sex differences in the relation of visceral adipose tissue accumulation to total body fatness. Am J Clin Nutr 1993;58:463-7.DOIPubMed
48. Laughlin GA, Barrett-Connor E, May S. Sex-specific association of the androgen to oestrogen ratio with adipocytokine levels in older adults: the Rancho Bernardo Study. Clin Endocrinol (Oxf) 2006;65:506-13.DOIPubMed
49. Manieri E, Herrera-Melle L, Mora A, et al. Adiponectin accounts for gender differences in hepatocellular carcinoma incidence. J Exp Med 2019;216:1108-19.DOIPubMedPMC
50. Lönnqvist F, Nordfors L, Jansson M, Thörne A, Schalling M, Arner P. Leptin secretion from adipose tissue in women. Relationship to plasma levels and gene expression. J Clin Invest 1997;99:2398-404.DOIPubMedPMC
51. Augustine LM, Fisher CD, Lickteig AJ, et al. Gender divergent expression of Nqo1 in Sprague Dawley and August Copenhagen x Irish rats. J Biochem Mol Toxicol 2008;22:93-100.DOIPubMed
52. Kratschmar DV, Calabrese D, Walsh J, et al. Suppression of the Nrf2-dependent antioxidant response by glucocorticoids and 11beta-HSD1-mediated glucocorticoid activation in hepatic cells. PLoS One 2012;7:e36774.DOIPubMedPMC
53. Hofer T, Karlsson HL, Möller L. DNA oxidative damage and strand breaks in young healthy individuals: a gender difference and the role of life style factors. Free Radic Res 2006;40:707-14.DOIPubMed
54. Naugler WE, Sakurai T, Kim S, et al. Gender disparity in liver cancer due to sex differences in MyD88-dependent IL-6 production. Science 2007;317:121-4.DOIPubMed
55. Yasuda M, Shimizu I, Shiba M, Ito S. Suppressive effects of estradiol on dimethylnitrosamine-induced fibrosis of the liver in rats. Hepatology 1999;29:719-27.DOIPubMed
56. Xie G, Wang X, Zhao A, et al. Sex-dependent effects on gut microbiota regulate hepatic carcinogenic outcomes. Sci Rep 2017;7:45232.DOIPubMedPMC
57. Tenkorang MA, Snyder B, Cunningham RL. Sex-related differences in oxidative stress and neurodegeneration. Steroids 2018;133:21-27.DOIPubMedPMC
58. Liu P, Xie SH, Hu S, et al. Age-specific sex difference in the incidence of hepatocellular carcinoma in the United States. Oncotarget 2017;8:68131-7.DOIPubMedPMC
59. Santos-Marcos JA, Rangel-Zuniga OA, Jimenez-Lucena R, et al. Influence of gender and menopausal status on gut microbiota. Maturitas 2018;116:43-53.DOIPubMed
60. Santos-Marcos JA, Haro C, Vega-Rojas A, et al. Sex differences in the gut microbiota as potential determinants of gender predisposition to disease. Mol Nutr Food Res 2019;63:e1800870.DOIPubMed
61. Kim YS, Unno T, Kim BY, et al. Sex differences in gut microbiota. World J Mens Health 2020;38:48-60.DOIPubMedPMC
62. Hassan MM, Botrus G, Abdel-Wahab R, et al. Estrogen replacement reduces risk and increases survival times of women with hepatocellular carcinoma. Clin Gastroenterol Hepatol 2017;15:1791-9.DOIPubMedPMC
63. Sukocheva OA. Estrogen, estrogen receptors, and hepatocellular carcinoma: are we there yet? World J Gastroenterol 2018;24:1-4.DOIPubMedPMC
64. Kalra M, Mayes J, Assefa S, et al. Role of sex steroid receptors in pathobiology of hepatocellular carcinoma. World J Gastroenterol 2008;14:5945-61.DOIPubMedPMC
65. Villa E, Camellini L, Dugani A, et al. Variant estrogen receptor messenger RNA species detected in human primary hepatocellular carcinoma. Cancer Res 1995;55:498-500.PubMed
66. Jonas S, Bechstein WO, Heinze T, et al. Female sex hormone receptor status in advanced hepatocellular carcinoma and outcome after surgical resection. Surgery 1997;121:456-61.DOIPubMed
67. Chow PK, Tai BC, Tan CK, et al. High-dose tamoxifen in the treatment of inoperable hepatocellular carcinoma: a multicenter randomized controlled trial. Hepatology 2002;36:1221-6.DOIPubMed
68. Barbare JC, Bouche O, Bonnetain F, et al. Randomized controlled trial of tamoxifen in advanced hepatocellular carcinoma. J Clin Oncol 2005;23:4338-46.DOIPubMed
69. Villa E, Dugani A, Fantoni E, et al. Type of estrogen receptor determines response to antiestrogen therapy. Cancer Res 1996;56:3883-5.PubMed
70. Wu Y, Yao N, Feng Y, et al. Identification and characterization of sexual dimorphismlinked gene expression profile in hepatocellular carcinoma. Oncol Rep 2019;42:937-52.DOIPubMedPMC
71. Villa E, Moles A, Ferretti I, et al. Natural history of inoperable hepatocellular carcinoma: estrogen receptors’ status in the tumour is the strongest prognostic factor for survival. Hepatology 2000;32:233-8.DOIPubMed
72. Natri HM, Wilson MA, Buetow KH. Distinct molecular etiologies of male and female hepatocellular carcinoma. BMC Cancer 2019;19:951.DOIPubMedPMC
73. Li CH, Haider S, Shiah YJ, et al. Sex differences in cancer driver genes and biomarkers. Cancer Res 2018;78:5527-37.DOIPubMed
Lonardo A, Ballestri S, Chow PKH, Suzuki A. Sex disparity in hepatocellular carcinoma owing to NAFLD and non-NAFLD etiology: epidemiological findings and pathobiological mechanisms. Hepatoma Res 2020;6:83. http://dx.doi.org/10.20517/2394-5079.2020.89
Full-Text Views Each Month
PDF Downloads Each Month